Teva targets $6–7 billion in innovative medicines revenue by 2030 as it outlines expanded R&D strategy

Teva has unveiled an expanded innovative-medicines strategy targeting $6–7 billion in annual revenue by 2030, supported by seven late-stage pipeline assets, potential annual launches and a broader R&D investment programme.

Teva Pharmaceutical Industries outlined its updated research and development strategy on 11 November 2026, setting a target of $6–7 billion in annual innovative medicines revenue by 2030 and describing a potential cadence of one new innovative medicine launch each year over the following five years, supported by seven late-stage pipeline assets.

The company also highlighted more than $10 billion in combined potential peak sales across its pipeline, positive primary-endpoint results from a Phase IIa anti-IL-15 study in coeliac disease, innovative-medicines gross margin ambitions above 75% and a free cash flow target exceeding $3.5 billion by 2030, with all financial projections and future launches remaining forward-looking rather than achieved outcomes.

Field	Content
Article Type	Industry Updates
Company	Teva Pharmaceutical Industries
Event	Research and Development Day strategy update
Announcement Date	11 November 2026
Industry Segment	Innovative pharmaceutical medicines
Strategic Focus	Expansion of innovative medicines research, development and commercialisation
Innovative Medicines Revenue Target	$6–7 billion annually by 2030
Revenue Target Year	2030
Revenue Target Status	Forward-looking company objective
Potential Launch Cadence	Approximately one new innovative medicine annually over the next five years
Launch Forecast Status	Potential; not guaranteed
Late-Stage Pipeline Assets	Seven
Combined Potential Peak Sales	More than $10 billion
Peak Sales Estimate Status	Company estimate; non-risk-adjusted and not achieved sales
Highlighted Research Programme	Anti-IL-15 programme for coeliac disease
Highlighted Clinical Study	Phase IIa coeliac disease study
Reported Clinical Outcome	Primary endpoint met
Study Efficacy Details	Not specified in supplied summary
Innovative Medicines Gross Margin Ambition	Above 75%
Free Cash Flow Target	More than $3.5 billion by 2030
Free Cash Flow Target Status	Forward-looking financial objective
Therapeutic Portfolio Scope	Multiple innovative medicines programmes
Geographic Revenue Scope	Not specified in supplied summary
Strategic Time Horizon	Through 2030
New Regulatory Approval	No new medicine approval announced as part of the strategy update
What Happened	Teva presented updated R&D priorities, pipeline ambitions and financial targets for innovative medicines.
Why It Matters	The strategy signals Teva's intention to expand the contribution of innovative medicines to its future business and growth profile.
Industry Significance	Illustrates a major pharmaceutical company's emphasis on late-stage innovation, pipeline productivity and higher-value medicines.
Financial Clarification	The $6–7 billion revenue figure is a 2030 target rather than transaction consideration or realised revenue.
Pipeline Clarification	The more than $10 billion potential peak-sales estimate is not risk-adjusted or guaranteed.
Key Takeaway	Teva is targeting substantial innovative-medicines growth by 2030 through its late-stage pipeline and planned development programme.
What to Watch	Clinical readouts, regulatory submissions, launch execution, innovative-medicines revenue growth, margins and free cash flow performance.
Primary Source	Teva Pharmaceutical Industries
Primary Source URL	https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Shares-Innovative-Pipeline-Updates-and-Unveils-Path-to-Future-Growth-at-RD-Day-Targeting-67-Billion-in-Innovative-Medicines-Revenue-by-2030/default.aspx
Relevant Date	11 November 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com